Hepatology

Clinical evidence, research, and medical intelligence in Hepatology.

Liver organoid model maps Wolman disease tissue injury and gene rescue

Human iPSC-derived liver organoids reproduced Wolman disease pathology and showed that hepatocyte LIPA restoration can suppress ductular reaction and fibrosis programs.

By Dr. A. Nikhil Krishnan, MBBS · Oct 24, 2026 · 5 min read

Hepatology·Lancet

Liver Disease Diagnostics in Africa Expose Major Access Barriers

A narrative review maps liver disease diagnostics in Africa, where biopsy, elastography, and pathology access remain limited outside…

Oct 24, 2026

Hepatology·BMJ Open

MELD score gains age, neutrophils and HE grade for ACLF risk prediction

A new CATCH-LIFE-MELD model adds age, neutrophil count and hepatic encephalopathy grade to improve short-term ACLF prognosis prediction.

Oct 24, 2026

Hepatology·NLM Alerts

LiverTox catalogs incretin-based DPP-4 inhibitors by formula and structure

NCBI LiverTox lists the chemical formulas and structures of four incretin-based DPP-4 inhibitors used in diabetes care.

Oct 24, 2026

Hepatology·Cancer Cell

Short-Term Overfeeding Disrupts Intestinal Barrier in Healthy Men

Short-term overfeeding in healthy men disrupted small intestinal barrier integrity and activated hepatic immunity, pointing to a rapid…

Oct 23, 2026

Hepatology·Gut

Liver biopsy study links cellular senescence to alcohol-associated hepatitis

Paired biopsies and transcriptomics in alcohol-associated hepatitis show senescence rises with disease and falls with resolution, pointing to…

Oct 23, 2026

Hepatology·Nat Rev Onc

Plasma lipids for MASLD biomarker paper clears prolonged peer review

Nature’s peer review record shows a long revision cycle for a plasma lipid biomarker study in MASLD before…

Oct 22, 2026

Hepatology·JNCI

Autoimmune Hepatitis After Long-Term Denosumab in Hashimoto Thyroiditis

A case report describes autoimmune hepatitis after long-term denosumab in a patient with Hashimoto thyroiditis, raising safety questions…

Oct 22, 2026

Hepatology·Lancet

Simedeutirom improves MASH fibrosis outcomes in phase 2b Chinese trial

In a 52-week phase 2b trial, simedeutirom improved MASH histology without worsening fibrosis and showed no treatment-related serious…

Oct 22, 2026

Hepatology·Nat Immunol

Plasma lipids identified as non-invasive MASLD biomarkers in Indian cohort

A cross-sectional Indian study found plasma lipid signatures that separated healthy controls, No-MASH, and MASH with strong machine-learning…

Oct 22, 2026

Hepatology

Clinical evidence, research, and medical intelligence in Hepatology.

In Brief The 5-minute rounds

New hypertension guideline lowers the treatment threshold to 130/80 mm Hg.
Phase 3 GLP-1 trial reports a 20% cut in major adverse cardiac events.
FDA clears a next-generation CAR-T therapy for relapsed lymphoma.
Meta-analysis links early mobilisation to shorter ICU length of stay.
Rapid guidance broadens empiric antibiotics for suspected sepsis.